Oncolix

Oncolix

Pioneering new horizons in ovarian cancer treatment with a focus on autophagy through our innovative prolactin receptor antagonist.

Founded 2007 0-1 employees Venture round Total: $8.46M Biotechnology, Health Care +1

Oncolix, a clinical-stage biotechnology company founded in 2007, is currently focused on pioneering new horizons in ovarian cancer treatment. The company's slogan emphasizes its commitment to innovation in this field, particularly through the development of an innovative prolactin receptor antagonist, Prolanta. This drug, which acts as a prolactin receptor antagonist, operates through the mechanism of autophagy. At present, Oncolix is actively conducting a Phase I clinical trial targeting ovarian cancer, showcasing the company's dedication to advancing new treatment options in this critical area of healthcare. With a core focus on the biotechnology, health care, and pharmaceutical industries, Oncolix has garnered significant attention and support. The company secured a noteworthy $4.51M Venture Round investment on 22 January 2015, reflecting the confidence and interest of investors in Oncolix's innovative approach to cancer treatment. In summary, Oncolix's strategic focus on ovarian cancer treatment, coupled with its innovative drug and recent investment support, positions the company as a prominent player in the biotechnology and pharmaceutical sectors. The ongoing Phase I clinical trial and the investment received further highlight the potential impact of Oncolix's advancements in cancer treatment.

Funding Stage	Amount	Investors	Date
Venture Round	$4.51M	-	22 Jan 2015
Venture Round	$2.40M	-	24 Apr 2012
Venture Round	$1.50M	-	10 Oct 2011
Seed Round	$50.00K	-	17 Aug 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

$4.51M

22 Jan 2015

Venture Round

$2.40M

24 Apr 2012

Venture Round

$1.50M

10 Oct 2011

Seed Round

$50.00K

17 Aug 2011

FAQ About Oncolix

Pioneering new horizons in ovarian cancer treatment with a focus on autophagy through our innovative prolactin receptor antagonist.

Oncolix was founded in 2007.

Oncolix operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on clinical-stage, cancer treatment, Phase I clinical trial and ovarian cancer.

Oncolix has approximately 0-1 employees.

Oncolix has completed 4 funding rounds, raising a total of $8.46M. The latest funding stage is Venture round.

Top alternatives and competitors to Oncolix include Jounce Therapeutics, Inc., Kancera, Apexigen, Pacylex Pharmaceuticals, Inc., Glycyx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Oncolix and Jounce Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Oncolix

Funding Rounds & Investors (4)

Oncolix Alternatives & Competitors

FAQ About Oncolix